<DOC>
	<DOC>NCT01063816</DOC>
	<brief_summary>The purpose of this study is to determine the maximum tolerated dose of veliparib (ABT-888)and to establish the recommended Phase 2 dose of veliparib (ABT-888) when administered in combination with carboplatin and gemcitabine in subjects with advanced solid tumors.</brief_summary>
	<brief_title>A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically or cytologically confirmed solid tumors that are metastatic or unrespectable for which carboplatin/gemcitabine is a treatment option. Eastern Cooperative Group performance score of 0 to 2. Adequate hematologic, hepatic and renal function Subject has received up to 2 DNA damaging or cytotoxic regimens in the past five years Subject has received any anticancer therapy including chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy within 28 days prior to study administration. Subjects with known history of brain metastases and primary CNS tumors. Hypersensitivity reactions to platinum compounds or gemcitabine. Clinically significant and uncontrolled major medical conditions Active malignancy within the past 5 years except for any cancer in situ cured or nonmelanoma carcinoma of the skin.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PARP Inhibitors</keyword>
</DOC>